Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246622 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01246622 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 32 participants.
The verdict
NCT01246622, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of lenalidomide when given together with cytarabine in treating patients with relapsed or refractory acute myeloid leukemia (AML). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cytarabine may kill more cancer cells
Interventions
- DRUG lenalidomide
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-02-07 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246622
The ClinicalTrials.gov registry entry for NCT01246622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lenalidomide is the first listed.
NCT01246622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246622 about?
NCT01246622 is a clinical study titled "Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial is studying the side effects and best dose of lenalidomide when given together with cytarabine in treating patients with relapsed or refractory acute myeloid leukemia (AML). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop canc...
What is the current status of trial NCT01246622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-02-07. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT01246622?
The interventions under investigation include: lenalidomide (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT01246622?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.